← Back to Screener
Dermata Therapeutics, Inc. Common Stock (DRMA)
Price$1.34
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-63.93%
Price vs S&P 500 (4W)-7.23%
VGM Score36.02
Market Capitalization$5.23M
All Metrics
Book Value / Share (Quarterly)$1.59
P/TBV (Annual)0.38x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.06
Price vs S&P 500 (YTD)-54.90%
EPS (TTM)$-5.43
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-5.43
EPS (Annual)$-8.16
ROI (Annual)-121.45%
Cash / Share (Quarterly)$1.73
ROA (Last FY)-96.12%
EBITD / Share (TTM)$-4.18
ROE (5Y Avg)-253.80%
Cash Flow / Share (Annual)$-2.92
P/B Ratio0.82x
P/B Ratio (Quarterly)0.76x
Net Income / Employee (Annual)$-839,800
Net Interest Coverage (TTM)-172.30x
ROA (TTM)-105.06%
EPS Incl Extra (Annual)$-8.16
Current Ratio (Annual)4.79x
Quick Ratio (Quarterly)6.67x
3-Month Avg Trading Volume1.40M
52-Week Price Return-82.24%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.01
52-Week High$8.00
EPS Excl Extra (Annual)$-8.16
26-Week Price Return-48.00%
Quick Ratio (Annual)4.59x
13-Week Price Return4.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.09x
Enterprise Value$-1.72M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.83
3-Month Return Std Dev77.61%
Net Income / Employee (TTM)$-789,200
ROE (Last FY)-121.45%
Net Interest Coverage (Annual)-67.40x
EPS Basic Excl Extra (Annual)$-8.16
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.43
ROI (TTM)-127.91%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.82
Price vs S&P 500 (52W)-110.45%
Year-to-Date Return-43.97%
5-Day Price Return3.17%
EPS Normalized (Annual)$-8.16
ROA (5Y Avg)-149.58%
Month-to-Date Return-5.11%
Cash Flow / Share (TTM)$-1.17
EBITD / Share (Annual)$-8.39
ROI (5Y Avg)-253.80%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.43
P/TBV (Quarterly)0.35x
P/B Ratio (Annual)0.38x
Book Value / Share (Annual)$2.34
Price vs S&P 500 (13W)-5.75%
Beta0.71x
Revenue / Share (TTM)$0.00
ROE (TTM)-127.91%
52-Week Low$1.10
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.48est. -0.54
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DRMADermata Therapeutics, Inc. Common Stock | — | — | D | $1.34 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Dermata Therapeutics develops OTC dermatology treatments for acne, psoriasis, rosacea, and seborrheic dermatitis. The company is advancing a once-weekly acne treatment leveraging its proprietary Spongilla technology platform for enhanced delivery and patient compliance. Dermata plans to expand Spongilla's application across dermatologic and aesthetic markets, including intradermal delivery of botulinum toxin, providing multiple revenue opportunities.